Ozempic maker Novo Nordisk pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price decline and impatience at the nonprofit ...

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years in the role, during which he led the company to an all-time high in the markets. Despite being the first to ...

Monday’s stock decline reflects specific challenges facing Novo Nordisk rather than fundamental problems with the obesity treatment market or the company’s long-term prospects.

Novo Nordisk (NYSE: NVO) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight ... The board cited these "recent market challenges Novo Nordisk has been ...

Novo Nordisk and its chief executive are parting ways after recent market challenges and a sharp decline in the company's share price over the past 12 months. Lars Fruergaard Jorgensen, who has ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S. telehealth company Hims & Hers Health, pushing Hims shares down 31% in morning trading.

Novo Nordisk and its chief executive are parting ways after recent market challenges and a sharp decline in the company's share price over the past 12 ... This Stock Is Cheap, High-Yielding, ...